让步
发表于 2025-3-23 10:34:32
Richard D. Beegle,Laurie M. Brown,David A. Weinstein
FLOUR
发表于 2025-3-23 15:35:04
A. Ferrand,V. M. Siu,C. A. Rupar,M. P. Napier,O. Y. Al-Dirbashi,P. Chakraborty,C. Prasad
badinage
发表于 2025-3-23 20:19:03
http://reply.papertrans.cn/51/5001/500056/500056_13.png
巨硕
发表于 2025-3-23 23:32:13
http://reply.papertrans.cn/51/5001/500056/500056_14.png
curettage
发表于 2025-3-24 05:21:51
Gianluigi Mazzoccoli,Tommaso Mazza,Manlio Vinciguerra,Stefano Castellana,Maurizio Scarpa
LIMIT
发表于 2025-3-24 07:24:27
http://reply.papertrans.cn/51/5001/500056/500056_16.png
烧烤
发表于 2025-3-24 12:49:12
Danique van Vliet,Esther van Dam,Margreet van Rijn,Terry G. J. Derks,Gineke Venema-Liefaard,Marrit M
kyphoplasty
发表于 2025-3-24 16:55:39
Amy Brown,Louise Crowe,Miriam H. Beauchamp,Vicki Anderson,Avihu Boneh
看法等
发表于 2025-3-24 21:24:44
Allan Bayat,Mette Christensen,Flemming Wibrand,Morten Duno,Allan Lund
lymphoma
发表于 2025-3-24 23:41:19
,Growth Charts for Individuals with Mucopolysaccharidosis VI (Maroteaux–Lamy Syndrome),5th, 50th, 75th, 90th, and 95th percentiles were constructed for patients with rapidly and slowly progressing disease defined by the pre-enzyme replacement therapy (ERT) uGAG levels of > or ≤200 μg/mg creatinine. The mean (SD) pre-ERT uGAG levels were 481.0 (218.6) and 97.8 (56.3) μg/mg creatinine f